Session: 802. Chemical Biology and Experimental Therapeutics: Poster III
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, Combination therapy, Translational Research, Drug development, Diseases, Treatment Considerations, Myeloid Malignancies, Biological Processes
To evaluate the therapeutic potential of the MET inhibitors, we first assessed the cytotoxicity of these compounds. The inhibitors promoted apoptosis (Annexin V+) in primary bone marrow mononuclear cells (BMNCs) from AML patients (p=.0059) without significant effect on healthy cells. In AML cell lines, Molm-13 (FAB M5a, MLL-AF9-mutated) and OCI-AML3 (FAB M4, NPM1-mutated), treatment with MET inhibitors resulted in low IC50 values (<10µM) and increased apoptosis rates (50% increase, p<.0001), indicative of a potent activity. Moreover, an aggressive MLL-AF9-driven AML model was employed to evaluate the efficacy of the MET inhibitors. The treatment reduced in 50% and 92% the proliferation of total AML cells and the phenotypic LSCs (Lineage−CD127−Sca1MLL-AF9-GFP+c-KithighCD34+CD16/32high) in vitro (p<.0001), respectively. To validate these findings in a pathophysiological setting, leukemic C57BL/6 mice bearing MLL-AF9-driven AML received daily intraperitoneal injections of the MET inhibitors (10mg/kg) for 5 days. Strikingly, the C1000 compound demonstrated the most potent effect, significantly inhibiting in 70% the proliferation of AML cells and LSCs in the BM, spleen, and peripheral blood (p<.0001).
Building on these findings, we investigated the effects of these MET inhibitors within the BM niche, where the microenvironment benefits AML cell survival. Molm-13 and OCI-AML3 cells were cocultured with primary BM MSCs to simulate the BM niche conditions. Remarkably, after treatment with MET inhibitors, the HGF signal was reduced on the AML cell surface, indicating disruption of the HGF/MET interaction. To gain a more nuanced understanding of these effects, we employed a 3D vascular and perivascular niche-mimicking co-culture model with AML cells. The treatment successfully overcame the protective effect of the niche cells (endothelial cells and MSCs), as evidenced by a 71% reduction in Molm-13 and blasts from AML patients (p<.0001). Finally, to explore the practical application of the C1000 compound for a combinatory therapy approach, AML cell lines were treated with C1000 alone or in combination with Venetoclax, a BCL2 inhibitor currently used for the treatment of AML patients who are ineligible for intensive chemotherapy. Synergy analysis performed using the Synergy Finder package in R revealed a synergistic interaction between C1000 and Venetoclax compounds (Bliss, ZIP, Loewe, HAS synergy scores >10). Taken altogether, our data demonstrate that MET inhibitors exhibit potent anti-neoplastic activity against aggressive AML models without harming healthy cells. Additionally, C1000 synergizes with Venetoclax compound, suggesting a promising therapeutic opportunity for combined chemotherapy regimens.
Funding: FAPESP 2017/21801-2, 2019/25247-5, 2021/05320-0, 2022/14101-2; CNPq 303405/2018-0.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts